请输入您要查询的百科知识:

 

词条 Estriol succinate
释义

  1. Medical uses

     Available forms 

  2. Side effects

  3. Pharmacology

  4. Chemistry

  5. History

  6. Society and culture

     Generic names  Brand names  Availability 

  7. Research

  8. References

{{Distinguish|Estradiol hemisuccinate}}{{Drugbox
| Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = 4[(8R,9S,13S,14S,16R,17R)-17-(3-carboxypropanoyloxy)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]oxy4-oxobutanoic acid
| image = Estriol disuccinate.svg
| width = 250px
| image2 = Estriol succinate molecule ball.png
| width2 = 250px
| tradename = Synapause, others
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration = By mouth, vaginal[1]
| class = Estrogen; Estrogen ester
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref =
| CAS_number = 514-68-1
| CAS_supplemental =
| ATC_prefix =
| ATC_suffix =
| PubChem = 10577
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 10133
| UNII = AS13K2DY03
| KEGG = D07920
| ChEBI = 135790
| synonyms = Oestriol succinate; Estriol disuccinate; Estriol hemisuccinate; Estriol 16α,17β-di(hydrogen succinate)
| C=26 | H=32 | N= | O=9
| molecular_weight = 488.533 g/mol
| SMILES = C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
| StdInChI_Ref =
| StdInChI = 1S/C26H32O9/c1-26-11-10-17-16-5-3-15(27)12-14(16)2-4-18(17)19(26)13-20(34-23(32)8-6-21(28)29)25(26)35-24(33)9-7-22(30)31/h3,5,12,17-20,25,27H,2,4,6-11,13H2,1H3,(H,28,29)(H,30,31)/t17-,18-,19+,20-,25+,26+/m1/s1
| StdInChIKey_Ref =
| StdInChIKey = VBRVDDFOBZNCPF-BRSFZVHSSA-N
}}Estriol succinate, sold under the brand name Synapause among others, is an estrogen medication which is used in the treatment of menopausal symptoms.[1] It is taken by mouth, in through the vagina, and by injection.[1][4][5]

Medical uses

Estriol succinate is used in menopausal hormone therapy in the treatment and prevention of menopausal symptoms such as hot flashes, vaginal atrophy, and osteoporosis.[1] Unlike other estrogens, depending on how it is used (i.e., how often it is taken and at what dosage), estriol succinate may not require concomitant therapy with a progestogen to prevent endometrial hyperplasia and endometrial cancer in women with intact uteruses.[1]

Available forms

Estriol succinate is and has been available in the form of 2 and 4 mg oral tablets, as a 0.1% vaginal cream, and as a 20 mg vial for use by injection.[2][3]

Side effects

{{See also|Estriol (medication)#Side effects}}

Pharmacology

{{See also|Estriol (medication)#Pharmacology}}

Estriol succinate is an estrogen ester, specifically, an ester of estriol, and acts as a prodrug of estriol in the body.[10][1] It is described as a weak estrogen in comparison to estradiol valerate.[1][4] Estriol succinate is used medically via oral and vaginal routes similarly to estriol.[1] In estriol succinate, two of the hydroxyl groups of estriol, those at the C16α and C17β positions, are esterified with succinic acid.[1] As such, a dose of 2 mg estriol succinate is equivalent to 1.18 mg unconjugated estriol.[1] Unlike other estrogen esters, such as estradiol valerate, estriol succinate is nearly not hydrolyzed in the intestinal mucosa, and in relation to this, is absorbed more slowly than is estriol.[1] Instead of in the gastrointestinal tract, estriol succinate is cleaved into estriol mainly in the liver.[1] After a single 8 mg oral dose of estriol succinate, maximum levels of circulating estriol of 40 pg/mL are attained within 12 hours, and this increases up to 80 pg/mL with continued daily administration.[1]

{{Oral potencies of estrogens}}

Chemistry

{{See also|List of estrogen esters#Estriol esters}}

Estriol succinate, also known as estriol disuccinate or as estriol 16α,17β-di(hydrogen succinate), is a synthetic estrane steroid and a derivative of estriol.[10][21][22] It is specifically the C16α and C17β disuccinate ester of estriol.[10][21][22][1] The medication is provided both as estriol succinate and as estriol sodium succinate, the sodium salt.[10][21] Other marketed estriol esters besides estriol succinate include estriol acetate benzoate and estriol tripropionate, whereas estriol dihexanoate, estriol dipropionate, and estriol triacetate are estriol esters that were never marketed.[10][21] Quinestradol is an estriol ether and has also been marketed.[10][21] Polyestriol phosphate is an ester of estriol in the form of a polymer, and was previously marketed.[5][6][7][8]

History

Estriol succinate was introduced for medical use in 1966.[37]

Society and culture

Generic names

Estriol succinate is the generic name of the drug and its {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|BAN|British Approved Name}}.[9][10][11][12][13] Other synonyms include oestriol succinate, estriol disuccinate, and estriol hemisuccinate.[9][10][11][12] When provided as the sodium salt, estriol succinate is known as estriol sodium succinate ({{abbrlink|BAN|British Approved Name}}) or as oestriol sodium succinate.[9][10]

Brand names

Estriol succinate has been marketed under brand names including Blissel, Evalon, Gelistrol, Hemostyptanon, Orgastyptin, Ovestin, Sinapause, Styptanon, Synapsa, Synapasa, Synapausa, and Synapause, among others.[9][10][11][12] Estriol sodium succinate has been marketed specifically under the brand names Pausan and Styptanon.[9][10]

Availability

Estriol succinate is or has been marketed in Europe, Hong Kong, and Mexico.[10][12]

Research

Estriol succinate was under development for the treatment of multiple sclerosis in the United States and worldwide, and reached phase II clinical trials for this indication, but development was discontinued due to insufficient effectiveness.[14] It had the tentative brand name Trimesta.[14]

References

1. ^10 11 12 13 {{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}
2. ^{{cite book|author1=R. S. Satoskar|author2=S. D. Bhandarkar &nirmala N. Rege|title=Pharmacology and Pharmacotherapeutics|url=https://books.google.com/books?id=7d493VOD4P8C&pg=PA934|year=1973|publisher=Popular Prakashan|isbn=978-81-7991-527-1|pages=934–}}
3. ^{{cite book|author1=Axel Kleemann|author2=Jürgen Engel|title=Pharmaceutical substances: syntheses, patents, applications|url=https://books.google.com/books?id=xYRUAAAAMAAJ|year=2001|publisher=Thieme|isbn=978-3-13-558404-1|page=786}}
4. ^{{cite book|author1=Winnifred Berg Cutler|author2=Celso-Ramón García|title=The medical management of menopause and premenopause: their endocrinologic basis|url=https://books.google.com/books?id=79lsAAAAMAAJ|year=1984|publisher=Lippincott Williams & Wilkins|isbn=978-0-397-50631-6|page=31}}
5. ^{{cite journal | vauthors = Lauritzen C, Velibese S | title = Clinical investigations of a long-acting oestriol (polyoestriol phosphate) | journal = Acta Endocrinol. | volume = 38 | issue = 1 | pages = 73–87 | date = September 1961 | pmid = 13759555 | doi = 10.1530/acta.0.0380073 | url = }}
6. ^{{cite journal | vauthors = Bachmann FF | title = Behandlung klimakterisher Beschwerden mit Polyöstriolphosphat | trans-title = Treatment of menopausal complants with polyoestriol-phosphate. Experiences with Gynäsan injections | language = German | journal = Munch Med Wochenschr | volume = 113 | issue = 5 | pages = 166–9 | date = January 1971 | pmid = 5107471 | doi = | url = }}
7. ^{{cite book|author=A. Labhart|title=Clinical Endocrinology: Theory and Practice|url=https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA551|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-96158-8|pages=548,551|quote=The polymer of estradiol or estriol and phosphoric acid has an excellent depot action when given intramuscularly (polyestriol phosphate or polyestradiol phosphate) (Table 16). Phosphoric acid combines with the estrogen molecule at C3 and C17 to form a macromolecule. The compound is stored in the liver and spleen where the estrogen is steadily released by splitting off of the phosphate portion due to the action of alkaline phosphatase. [...] Conjugated estrogens and polyestriol and estradiol phosphate can also be given intravenously in an aqueous solution. Intravenous administration of ovarian hormones offers no advantages, however, and therefore has no practical significance. [...] The following duarations of action have been obtained with a single administration (WlED, 1954; LAURITZEN, 1968): [...] 50 mg polyestradiol phosphate ~ 1 month; 50 mg polyestriol phosphate ~ 1 month; 80 mg polyestriol phosphate ~ 2 months.}}
8. ^{{cite book|author=S. Campbell|title=The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London|url=https://books.google.com/books?id=WT3sCAAAQBAJ&pg=PA395|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-6165-7|pages=395–|quote=In the Federal Republic of Germany between 10 and 20% of all climacteric women are on estrogen treatment. We have the following oral estrogens for a treatment. (t) Conjugated estrogens, (2) estradiol valerate, (3) ethinyl-estradiol and its cyclopentyl-enol ether, (4) stilbestrol, (5) ethinyl-estradiol-methyltestosterone, (6) estriol and estriol succinate, most of them as coated tablets. Several long acting injectable preparations are available: several esters of combined estradiol-testosterone, one of estradiol-dehydroepiandrosterone enanthate and a prolonged polyestriol phosphate are also available. Lastly, depot injections of estradiol- and stilbestrol-esters are on the market.}}
9. ^10 {{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA129|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|page=899}}
10. ^10 {{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA407|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=407–}}
11. ^{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA114|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=114–}}
12. ^https://www.drugs.com/international/estriol.html
13. ^{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1481|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=1481–}}
14. ^https://adisinsight.springer.com/drugs/800026520
{{Estrogens and antiestrogens}}{{Estrogen receptor modulators}}

6 : Esters|Estranes|Estriol esters|Estrogens|Phenols|Triols

随便看

 

开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。

 

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间:2024/11/13 0:00:51